0001226616falseDE00012266162024-06-112024-06-11

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

001-33185

33-0927979

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

4275 EXECUTIVE SQUARE,

SUITE 300, LA JOLLA, CA

92037

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 373-1500

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.001 par value

MNOV

The Nasdaq Stock Market LLC

 

 

(Title of each class)

(Trading symbol(s))

(Name of each exchange on which registered)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

MediciNova, Inc. (the “Company”) held its 2024 annual meeting of stockholders on June 11, 2024 (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 26, 2024 (the “Proxy Statement”).

At the close of business on April 17, 2024, the record date of the Annual Meeting, the Company had 49,046,246 shares of common stock issued and outstanding. The holders of a total of 35,566,042 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.

Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting

(1)

To elect two Class II Director nominees named below to serve until the 2027 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until his or her earlier death, resignation or removal. The named nominees were so elected, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

 

Nominees

For

Against

Abstain

Broker Non-Vote

Yuichi Iwaki

24,341,478

7,902,443

886,701

2,435,420

Kazuko Matsuda

24,576,097

7,667,575

886,949

2,435,421

 

(2)

To ratify the selection of BDO USA, P.C. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. This proposal was approved, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

For

Against

Abstain

Broker Non-Vote

27,390,814

 

7,519,216

 

654,012

 

2,000

 

 

 

 

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

By:

/s/ Yuichi Iwaki

Yuichi Iwaki

President and Chief Executive Officer

Date: June 12, 2024

 

 

 

v3.24.1.1.u2
Document and Entity Information
Jun. 11, 2024
Cover [Abstract]  
Entity Registrant Name MEDICINOVA, INC.
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0001226616
Document Type 8-K
Document Period End Date Jun. 11, 2024
Entity File Number 001-33185
Entity Tax Identification Number 33-0927979
Entity Address, Address Line One 4275 EXECUTIVE SQUARE
Entity Address, Address Line Two SUITE 300
Entity Address, City or Town LA JOLLA
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 373-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol MNOV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Medicinova (NASDAQ:MNOV)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Medicinova
Medicinova (NASDAQ:MNOV)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Medicinova